As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $10.20, down -14.14% from its previous closing price of $11.88. On the day, 4158270 shares were traded.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.80 and its Current Ratio is at 7.08. In the meantime, Its Debt-to-Equity ratio is 2.32 whereas as Long-Term Debt/Eq ratio is at 2.31.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on January 03, 2024, Upgraded its rating to Buy and sets its target price to $8 from $4 previously.
On October 26, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $57 to $4.
Goldman Downgraded its Buy to Neutral on October 13, 2023, whereas the target price for the stock was revised from $32 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 04 ’24 when Heron Patrick J bought 21,052 shares for $9.50 per share. The transaction valued at 199,994 led to the insider holds 8,785,284 shares of the business.
Watanabe Todd Franklin sold 14,903 shares of ARQT for $165,739 on Mar 04 ’24. The insider now owns 874,533 shares after completing the transaction at $11.12 per share. On Mar 04 ’24, another insider, Burnett Patrick, who serves as the insider of the company, sold 4,782 shares for $11.12 each. As a result, the insider received 53,182 and left with 269,300 shares of the company.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $15.40, while it has fallen to a 52-week low of $1.76.
Shares Statistics:
A total of 114.97M shares are outstanding, with a floating share count of 97.38M. Insiders hold about 15.30% of the company’s shares, while institutions hold 84.08% stake in the company.
Earnings Estimates
As of right now, Arcutis Biotherapeutics, Inc. analysts gave their recommendation on the stock of the company.
